Source: The Insides Company Limited
On: 15 June 2023
Organisations: Ministère de la Santé et de la Prévention, The Insides® Company Limited
The Insides Company, a medical technology company focused on the development and commercialisation of novel chyme reinfusion therapy (CRT) devices for the treatment of intestinal failure, today announced they have received ‘prise en charge transitoire’ (PECT) reimbursement in France. PECT reimbursement is approval for the early coverage of innovative medical technologies where relevant clinical and medico-economic evidence is expected to be rapidly available.
This interim reimbursement issued by the Ministère de la Santé et de la Prévention allows ‘The Insides System’ to be reimbursed in France for the treatment of type II intestinal failure. This enables The Insides Company to support patients in France who suffer from type II intestinal failure, whilst pursuing ‘liste des produits et prestations remboursables’ (LPPR) reimbursement.
Garth Sutherland, CEO of The Insides Company, commented, “We are very appreciative of the Ministère de la Santé et de la Prévention for supporting this innovation and the guidance by MediTech Access through this process. France has always been at the forefront of chyme reinfusion innovation, including the pivotal studies conducted by Dr Etienne Levy and colleagues in the 1970’s and 1980’s, and more recently by Dr Denis Picot and colleagues. It is our privilege to provide innovative therapeutic medical devices in support of these foundation achievements to enable the best possible outcomes for patients who have suffered an intestinal catastrophe”.
About Type II Intestinal Failure and Chyme Reinfusion Therapy
Type II intestinal failure is the inability of the gut to absorb necessary water, macronutrients, micronutrients, and electrolytes to sufficiently sustain life without intravenous supplementation or replacement. This can be due to malabsorption (small bowel mucosal disease), surgical resection (short bowel syndrome), fistulae, dysmotility, or mechanical obstruction. Under the standard care pathway, patients recovering from colorectal surgery often have an enterostomy created to divert intestinal contents (chyme) away from the surgical site as it heals. The enterostomy is typically left open for 6-12 months, and during this time the chyme that is collected is disposed of, which can result in intestinal failure and other complications.
The Insides System is a purpose-built medical device for performing chyme reinfusion therapy. Chyme reinfusion is a practice in the management of patients with high-output enterocutaneous fistulas, and high-output enterostomies. It enables patients to re-commence oral feeding, resulting in significant clinical benefits, health economic benefits, and improvements in patient quality of life.
About The Insides Company
The Insides Company has commercialised 30 years of clinical experience in gut nutrition into breakthrough medical devices. Innovations in chyme reinfusion therapy, including the triple stoma technique, were developed by Professor Ian Bissett in the 1980s during his time as a general surgeon in Nepal. During this experience, he observed an unmet clinical need in patients who were severely malnourished as a result of intestinal failure. The Insides Company’s mission is to provide universal access to chyme reinfusion therapy through revolutionary products and education to establish a new standard of care.
The Insides Company
Garth Sutherland, CEO
Phone: +64 9 887 9309